Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Call Transcript October 30, 2024Corcept Therapeutics Incorporated beats earnings expectations.
Corcept Therapeutics Inc (CORT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 6,509,002 | $301,236,613 | -6% | 0.45% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,580,621 | $73,151,140 | +7% | 0.06% |
| 3. | D E Shaw D. E. Shaw | 788,064 | $36,471,602 | -17% | 0.03% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 457,100 | $21,154,588 | -12% | 0.04% |
| 5. | Royce & Associates Chuck Royce | 363,272 | $16,812,228 | +4% | 0.15% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.53 | 100,000 | Director | 3,308,303 | 2021-06-11 | Filing | |
| $21.53 | 50,000 | Director | 1,046,838 | 2021-06-11 | Filing | |
| $22.64 | 68 | Director | 3,208,303 | 2020-12-01 | Filing | |
| $22.80 | 1,109 | Director | 3,208,235 | 2020-11-30 | Filing | |
| $22.81 | 361 | Director | 3,207,126 | 2020-11-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.88 | 2,200 | 0 | 2024-11-11 | Filing | ||
| $48.97 | 3,394 | 5,796 | 2024-11-04 | Filing | ||
| $48.97 | 6,606 | 5,796 | 2024-11-01 | Filing | ||
| $46.28 | 10,000 | 5,796 | 2024-10-01 | Filing | ||
| $46.28 | 11,000 | 22,772 | 2024-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,407,696 | $532,921,965 | 0.01% | |
| 2. | 9,537,532 | $309,779,039 | 0% | |
| 3. | 3,768,245 | $122,392,598 | 3.63% | |
| 4. | 3,387,465 | $110,024,863 | 0% | |
| 5. | 2,411,362 | $78,321,038 | 4.83% |
News See All
Does Corcept Therapeutics (CORT) Have a Long Runway for Growth?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Value Strategy” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2024 Earnings Call Transcript July 29, 2024Corcept Therapeutics Incorporated beats earnings expectations.
What Makes Corcept Therapeutics (CORT) a Good Investment Bet?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Value Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated beats earnings expectations. Reported EPS is $0.2503, expectations were $0.21.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript
Corcept Therapeutics Incorporated beats earnings expectations. Reported EPS is $0.28, expectations were $0.25.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2023 Earnings Call Transcript
Operator: Good day. And welcome to the Corcept Therapeutics Conference Call. At this time, all participants are in a listen-only mode.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2023 Earnings Call Transcript
Operator: Good day. And welcome to the Corcept Therapeutics Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Corcept Therapeutics conference call. After the speakers' presentation, there will be a question-and-answer session.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to the Corcept Therapeutics Conference Call. At this time, all participants are in a listen-only mode.